MELA Sciences, a Leader in the Fight Against Melanoma, Appoints Tony Dimun to Its Board of Directors

MELA Sciences, a Leader in the Fight Against Melanoma, Appoints Tony Dimun to
Its Board of Directors

IRVINGTON, N.Y., Sept. 30, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind®, the first and only FDA approved optical diagnostic
device for melanoma detection used by dermatologists in their fight against
melanoma, today announced that Tony Dimun, Chairman of Nascent Enterprises,
has been appointed as a Director and a member of the Company's Audit
Committee, effective as of October 1, 2013.

Mr. Dimun is a serial entrepreneur and has more than 30 years of successful
operational, business development, and financial experience in the healthcare
marketplace. During his last 20 years, he has been an investor and mentor to
several emerging growth medical enterprises that have matured to commercial
status and became publicly traded companies acting either as the Founder or
participating in the finding of 21 medical device companies. Of these
enterprises, four became public companies and eleven were acquired. Since
2001, he has served as Chairman of Nascent Enterprises, a group of medical
industry entrepreneurs focused on successful commercialization of promising
medical device inventions. From 1987 to 2001, he served as Executive Vice
President & Chief Financial Officer of Vital Signs, a publicly held
anesthesia, respiratory and sleep apnea medical device business. GE Medical
acquired Vital Signs in 2008 for approximately $900 million. Prior to 1991,
Mr. Dimun held positions as a Certified Public Accountant with national
accounting firms and served as Senior Vice President for an international
merchant banking firm specializing in mergers & acquisitions.

"We are thrilled to welcome Tony to our Board of Directors, and look forward
to his contribution to MELA Sciences. As a seasoned executive in the
healthcare industry, Tony has significant leadership experience managing
growing businesses, achieving sustainable revenue growth and driving
operational improvements. I believe he will bring meaningful value to MELA
Sciences and to our Board of Directors," said Robert Coradini, Interim Chief
Executive Officer of MELA Sciences.

"I am pleased to be joining MELA Sciences' Board of Directors, and look
forward to contributing to the company's success and commercial efforts," said
Mr. Dimun. "MELA Sciences is at an exciting stage in its development as a
company, and is emerging as a true leader in the field of diagnostic devices
for melanoma detection."

Mr. Dimun has been a director of several public companies, including Vital
Signs, Bionx Implants, Colorado MedTech, Photomedix, ISS Surgical Systems and
numerous privately held companies in the healthcare industry. He has also
served on the Board of Advisors of the Rutgers University Technology Center &
the Biomaterial Institute of Rutgers University and, through Nascent
Enterprises, provides the University of Pennsylvania and other universities
with entrepreneurial assistance to commercialize their medical technology.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind® and its further design and development.
MelaFind® is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind®
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind® has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit

Safe Harbor:

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at and

CONTACT: Investors
         Lynn Pieper
         Westwicke Partners
         Erica Sperling
         Rpr Marketing Communications
Press spacebar to pause and continue. Press esc to stop.